The Dermatology Digest

AUGUST 12, 2024

As a combined company, we have the opportunity to create a comprehensive portfolio of high-growth products for all stages of life, and we will be committed to investing in education, training, and practice support for aesthetics providers across the United States.” ” Mark J. ” Mark J.

Portfolios 69

Portfolios Innovations Marketing Office 69

The Dermatology Digest

MARCH 27, 2024

Alexis (Lexi) Stern is Merz Aesthetics’ new Chief Marketing Officer. Stern will join the global leadership team and will be responsible for leading the portfolio and brand strategies. Stern will report directly to Bob Rhatigan, Chief Executive Officer, Merz Aesthetics. Most recently, Ms.

Office 36

Office Portfolios Branding Marketing 36

The Dermatology Digest

MARCH 26, 2024

“While NCE status will provide YCANTH with a minimum of five years of protection, we anticipate our full patent portfolio to provide protection from generic competition for the next decade and potentially beyond,” says Ted White, Verrica’s President and Chief Executive Officer, in a news release.

Pharmaceutical 36

Pharmaceutical Portfolios Office Marketing 36

The Dermatology Digest

FEBRUARY 28, 2024

The new Consumer Skincare Division, led by Steve Gallopo, Executive Vice President and Chief Commercial Officer, will combine resources of the previously separate units. Crown Laboratories, Inc. is consolidating its Premium Skincare and Therapeutic business units into a single Consumer Skincare Division.

Skincare 36

Skincare Portfolios Innovations Office 36

The Dermatology Digest

APRIL 1, 2024

“We are excited to announce the addition of this collaboration for povorcitinib, expanding our relationship with CMS in the Dermatology space beyond ruxolitinib cream, to include two products with the potential to help patients with limited treatment options,” says Hervé Hoppenot, Chief Executive Officer, Incyte, in a news release.

Portfolios 36

Portfolios Injections Innovations Sales 36

The Dermatology Digest

JANUARY 2, 2024

Dennis Gross Skincare is the perfect complement to our global portfolio of prestige brands as their core values are aligned with ours in terms of their scientific and innovative approach to beauty and our people-first culture.”

Dermatology 36

Dermatology Sales Skincare Portfolios 36

AAAMS

FEBRUARY 22, 2023

Office politics are reduced as complex hierarchies are no longer present. You’ll Experience Enhanced Job Security In the world of finance, a diversified investment portfolio is the key to mitigating risk and creating greater financial stability. Practitioners are free and encouraged to exercise their best medical judgment.

Work-Life Balance 52

Work-Life Balance Training Office Marketing 52

Spa Executive

OCTOBER 23, 2024

Travelers don’t just want to choose their own adventure – they want to maximize every moment of their time away,” said Chris Nassetta, president and chief executive officer, Hilton. These findings highlight new opportunities for us to innovate across our global portfolio and further enhance guests’ stays.

Portfolios 52

Portfolios Technology Social Media Branding 52

Spa Executive

AUGUST 27, 2024

Roger Sholanki, Book4Time Founder and Chief Executive Officer, commented, “Over the past 20 years, we have worked hand-in-hand with the world’s leading hospitality brands in over 100 countries to develop the industry’s #1 SaaS platform for spa and wellness operations.

Management 52

Management Hospital Technology Sales 52

The Dermatology Digest

OCTOBER 1, 2024

“We are encouraged by the outcome from the recent FDA meeting and the opportunity to advance our development of prabotulinumtoxinA utilizing the 351(k) biosimilar regulatory pathway,” says Marc Forth, AEON’s President and Chief Executive Officer, in a news release. “We

Hydration 36

Hydration Portfolios Office Surgery 36

The Dermatology Digest

DECEMBER 21, 2023

and Europe will complement the recent launch of Nuceiva, our flagship neurotoxin, which has been met with very strong interest and growing demand from customers,” says David Moatazedi, President and Chief Executive Officer of Evolus, in a news release. “We “The addition of the Estyme facial fillers in the U.K.

Marketing 36

Marketing Sales Branding Portfolios 36

The Dermatology Digest

DECEMBER 21, 2023

and Europe will complement the recent launch of Nuceiva, our flagship neurotoxin, which has been met with very strong interest and growing demand from customers,” says David Moatazedi, President and Chief Executive Officer of Evolus, in a news release. “We “The addition of the Estyme facial fillers in the U.K.

Marketing 36

Marketing Sales Branding Portfolios 36

The Dermatology Digest

MARCH 5, 2024

Chief Executive Officer of Apogee, in a news release.

Injections 36

Injections Safety Sustainability Clinic 36

Aesthetics Advisor

SEPTEMBER 15, 2023

It’s pure commonsense ,” Nathan Jones, chief executive officer of Xlear said in a statement. We are very confident in these results that show Carragelose inactivates SARS-CoV-2, independent of the mutations we tested ,” said Dr. Eva Prieschl-Grassauer, Chief Scientific Officer at Marinomed.

Hospital 69

Hospital Clinic Marketing Medical 69

The Dermatology Digest

NOVEMBER 4, 2024

“The MDR CE Mark certification for Estyme , is a critical milestone in our strategic path to expand our product portfolio and reflects our commitment to delivering high-quality gels that adhere to the most rigorous regulatory standards,” says David Moatazedi, President and Chief Executive Officer of Evolus, in a news release.

Injections 68

Injections Medical Portfolios Branding 68

Spa Industry Association

MARCH 20, 2025

KNESKOs presence has grown from three pilot locations, to 40 spas in the Woodhouse Spa portfolio. Woodhouse Spa locations across the country continue to partner with KNESKO Masks as a premium enhancement that can be added to any treatment.

Partnerships 52

Partnerships Portfolios Innovations Office 52

The Dermatology Digest

APRIL 16, 2025

With the introduction of Evolysse, we are bringing together the fastest growing toxin in the category with the first new innovation in HA technology in over a decade, says David Moatazedi, President and Chief Executive Officer of Evolus, in a news release.

Injections 50

Injections Portfolios Innovations Technology 50

The Dermatology Digest

FEBRUARY 13, 2025

This milestone represents an exciting new chapter in our long-term strategy to expand our portfolio and transition from a single-product company to a multi-product innovator, strengthening our leadership in performance beauty, says David Moatazedi, President and Chief Executive Officer of Evolus, in a news release.

Injections 73

Injections Portfolios Safety Innovations 73

The Dermatology Digest

MARCH 27, 2025

We are thrilled to announce this agreement with Kaken, a dermatology leader with significant reach and expertise in the Japanese market, says Martin Babler, President and Chief Executive Officer of Alumis, in a news release. ESK-001 will be an important addition to the Kaken portfolio of novel therapeutics for dermatology conditions.

Pharmaceutical 36

Pharmaceutical Portfolios Clinic Safety 36